These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 3124451)

  • 41. Intratumoral LAK cell and interleukin-2 therapy of human gliomas.
    Barba D; Saris SC; Holder C; Rosenberg SA; Oldfield EH
    J Neurosurg; 1989 Feb; 70(2):175-82. PubMed ID: 2643685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
    West WH; Tauer KW; Yannelli JR; Marshall GD; Orr DW; Thurman GB; Oldham RK
    N Engl J Med; 1987 Apr; 316(15):898-905. PubMed ID: 3493433
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
    Mulé JJ; Shu S; Schwarz SL; Rosenberg SA
    Science; 1984 Sep; 225(4669):1487-9. PubMed ID: 6332379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
    Marcus SL; Dutcher JP; Paietta E; Ciobanu N; Strauman J; Wiernik PH; Hutner SH; Frank O; Baker H
    Cancer Res; 1987 Aug; 47(15):4208-12. PubMed ID: 3496958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
    Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
    J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
    Margolin KA; Rayner AA; Hawkins MJ; Atkins MB; Dutcher JP; Fisher RI; Weiss GR; Doroshow JH; Jaffe HS; Roper M
    J Clin Oncol; 1989 Apr; 7(4):486-98. PubMed ID: 2647914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
    Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
    Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
    Schwarz RE; Vujanovic NL; Hiserodt JC
    Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.
    Ishikawa T; Imawari M; Moriyama T; Ohnishi S; Matsuhashi N; Suzuki G; Takaku F
    J Cancer Res Clin Oncol; 1988; 114(3):283-90. PubMed ID: 2838488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial.
    Dillman RO; Oldham RK; Barth NM; Birch R; Arnold J; West WH
    J Natl Cancer Inst; 1990 Aug; 82(16):1345-9. PubMed ID: 2199682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK).
    Okamoto Y; Shimizu K; Tamura K; Miyao Y; Yamada M; Matsui Y; Tsuda N; Takimoto H; Hayakawa T; Mogami H
    Acta Neurochir (Wien); 1988; 94(1-2):47-52. PubMed ID: 3177046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
    Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.